Clinical Trials Browser

Phase 2 × Neoplasms × Standard of Care × Clear all

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT07023289 2026-03-13

A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease

Phase 2 Recruiting

140 enrolled

Gastrointestinal

Neoplasms, Colorectal Neoplasms

NCT06559228 2025-06-15

ConnectedNest: a Digital Platform Connecting Individuals With Cancer to Social Care

Phase 2 Recruiting

300 enrolled

Tumor-Agnostic

Neoplasms

NCT04295447 2024-06-20

ADAM

Phase 2 Active not recruiting

190 enrolled

Genitourinary

Neoplasms, Prostatic Neoplasms

NCT03469284 2023-04-25

MOM's PAIN (Methylene Blue for Oral Mucositis' PAIN)

Phase 2 Completed

69 enrolled 11 charts

Neoplasms, Stomatitis

NCT04333914 2022-09-30

IMMUNONCOVID

Phase 2 Completed

19 enrolled

COVID-19, Infections, Neoplasms

NCT01529411 2019-04-04

MAJA

Phase 2 Completed

86 enrolled

Genitourinary

Carcinoma, Carcinoma, Transitional Cell, Neoplasm Metastasis, Neoplasms

NCT01353222 2017-05-25

DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma

Phase 2 Terminated

142 enrolled 13 charts

Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Neoplasms, Neoplasms by Site, Ureteral Neoplasms, Urethral Neoplasms

Clinical Trials

I-SPY

A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease

ConnectedNest: a Digital Platform Connecting Individuals With Cancer to Social Care

ADAM

MOM's PAIN (Methylene Blue for Oral Mucositis' PAIN)

IMMUNONCOVID

MAJA

DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma